A veteran biopharma executive and former cardiothoracic surgeon is joining the company as its lead candidate S-969 progresses toward an IND submission.
RENO, NV, UNITED STATES, July 17, 2026 /EINPresswire.com/ — Sarcomatrix Therapeutics, a biopharma developer of new Duchenne muscular dystrophy (DMD) treatments, has named Jeff Myers, M.D., Ph.D., as Chief Medical Officer. Dr. Myers comes onboard while the company progresses its primary small-molecule candidate S-969 toward an Investigational New Drug (IND) filing and its first human clinical trials.
With over 15 years at the executive level, Dr. Myers has directed clinical development, regulatory strategy, medical affairs, and global clinical operations for biotech firms creating cutting-edge treatments. Before coming to Sarcomatrix, he held top executive positions, including Chief Medical Officer at Beyond Air, Revolo Biotherapeutics, and Portola Pharmaceuticals. Earlier in his professional life, he worked as a congenital cardiothoracic surgeon and was Chief of Pediatric Cardiac Surgery at Massachusetts General Hospital and Tulane University.
"Jeff's experience leading first-in-class therapies from development through clinical execution makes him an exceptional addition to our leadership team," said David Craig, Co-Founder and Chief Executive Officer of Sarcomatrix Therapeutics. "As we prepare to enter the clinic, his expertise in clinical development, regulatory strategy and translational medicine will be invaluable as we advance S-969 toward patients living with Duchenne muscular dystrophy."
In his role as Chief Medical Officer, Dr. Myers will offer strategic direction for Sarcomatrix's clinical development efforts, which encompasses finalizing the Phase I clinical plan, assisting with regulatory discussions, overseeing CRO selection, and aiding in moving the company's lead therapy toward clinical testing.
"I am excited to join Sarcomatrix at such an important stage in the company's evolution," Dr. Myers remarked. "The scientific foundation behind S-969 and the opportunity to potentially improve outcomes for patients living with Duchenne muscular dystrophy are incredibly compelling. I look forward to working alongside David and the entire team as we transition from preclinical development into the clinic."
S-969 is an oral small-molecule candidate still under investigation, designed to target the fundamental muscle degeneration caused by Duchenne muscular dystrophy—a rare, progressive neuromuscular condition that impacts roughly one in every 3,500 to 5,000 male births globally.
About Sarcomatrix Therapeutics
Sarcomatrix Therapeutics is a biopharmaceutical firm developing novel oral therapies for Duchenne muscular dystrophy and related neuromuscular conditions. Its lead investigational candidate, S-969, aims to enhance muscle function and decelerate disease progression via a unique mechanism of action. The company is progressing S-969 toward clinical development with the objective of delivering accessible treatments that enhance the lives of those affected by debilitating neuromuscular diseases.
Media Contact
Madelyn De Los Santos
Putnam Insights LLC
madelyn@putnaminsights.com
